Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C, et al
Recent Developments: In June 2025, Eli Lilly and Company entered a high-value partnership with Camurus to develop long-acting GLP-1 and dual/triple incretin therapies using Camurus proprietary FluidCrystal technology, with deal terms that could reach up to $870 million
Research published in Proceedings of the National Academy of Sciences found that melanocortin agonists trigger spontaneous sexual activity in test subjects
Clinical evidence shows that Ozempic is associated with a small increase in resting heart rate typically in the range of 2-3 beats per minute on average, as documented in the Summary of Product Characteristics
This article summarizes what research shows in specific clinical trial populations and what patterns may be worth tracking, not whether stopping is the right decision for you
Brain signaling: They bind to hypothalamus receptors, dialing down appetite signals by 3040%